Industry change
Bioepis and Proteina connect AI design with experimental validation
- Published
- Source
- Samsung Bioepis
- Source type
- Partnership
Summary
The companies announced an AI antibody discovery agreement, dividing discovery and preclinical responsibilities and targeting candidates by 2027. It does not establish drug efficacy or approval.
Why it matters for our work
An AI proposal and an experimentally validated result have different status. Research records should connect hypotheses, evidence and the next responsible person.
Translated from the Korean original. Summaries may be translated and edited. Commentary reflects our perspective; forecasts remain the source’s views.